Use of oxidase inhibitor with dextromethorphan to treat intractable coughing and dermatitis
CA 2114267 C · Owner: Smith, Richard A. · Inventors: Smith, Richard A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention discloses a method for increasing the effectiveness of dextromethorphan (DM) in treating either severe coughing or dermatitis which do not respond to other drug treatments. This method involves the administration to a , patient who is an extensive metabolizer of dextromethorphan and who is suffering from severe coughing or dermatitis of , dextromethorphan along with a second agent that inhibits the enzymatic activity of debrisoquin hydroxylase (also called sparteine monooxygenase, cytochrome P450DB and cytochrome , P450-2D6). Quinidine is an especially potent inhibitor of enzymatic DM oxidation, but it is not well tolerated by everyone. Other antioxidants which are …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 26, 1994 and granted May 17, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 26, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 26, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.